We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ask ADVFN Intelligence (AI)
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire FARMINGTON, Conn., May 2, 2023 - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share...
Suspension de la négociation par l'OCRCVM - IMV Canada NewsWire TORONTO, le 1er mai 2023 TORONTO, le 1er mai 2023 /CNW/ - L'OCRCVM a suspendu la négociation des titres suivants...
IIROC Trading Halt - IMV Canada NewsWire TORONTO, May 1, 2023 TORONTO, May 1, 2023 /CNW/ - The following issues have been halted by IIROC: Company: IMV Inc. TSX Symbol: IMV All Issues:...
TMX Group, IMV, C-Suite at The Open Canada NewsWire TORONTO, Dec. 9, 2020 TORONTO, Dec. 9, 2020 /CNW/ - Fred Ors, CEO, IMV Inc. (TSX: IMV), shares his company's story in an interview with TMX...
Sélectionnée par le gouvernement canadien pour recevoir un financement supplémentaire, portant le soutien à un total de 10 millions de dollars à ce jour pour le développement clinique et la...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious...
Rapidly progressing DPX-COVID-19, including Health Canada agreement on Phase 1 clinical study design protocol, with preliminary results expected in fall 2020 Confirmed $4.75M of non-dilutive...
Ces subventions d’un total de 4,75 millions soutiendront la fabrication du vaccin et l’étude clinique de phase 1 IMV Inc. (Nasdaq: IMV; TSX: IMV), une société biopharmaceutique (la « Société »...
Contribution totalling Cdn$4.75 Million will support Phase 1 clinical development and manufacturing of DPX-COVID-19 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company...
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 156 | -14.68 | -92.9113924051 | 15.8 | 19.3 | 0.62 | 21207 | 8.13459291 | CS |
| 260 | -40.88 | -97.3333333333 | 42 | 92.5 | 0.62 | 79270 | 38.20718509 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
